Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Exelixis

Status and phase

Completed

Phase 1

Conditions

Thyroid Carcinoma

Lymphoma

Cancer

Treatments

Drug: XL184

Study type

Interventional

Funder types

Industry

Identifiers

NCT00215605

XL184-001

Details and patient eligibility

About

The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration. To determine the highest safe dose, subjects will receive different amounts of the drug. The first group of subjects will receive the lowest dose of XL184. As long as no medically unacceptable side effects are noted, the dose will be increased for the next group. When the maximum tolerated dose (MTD) is reached, at least 20 subjects with Medullary Thyroid Cancer (MTC) will be enrolled to evaluate the effect of XL184 in this population.

Enrollment

85 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective
Eastern Cooperative Oncology Group (ECOG) performance status </= 2
Life expectancy greater than 3 months
Adequate organ and marrow function
Written informed consent
Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study
In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST

Exclusion criteria

Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184
Administration of an investigational drug within 30 days of the first dose of XL184
Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment
Known brain metastases
Uncontrolled intercurrent illness
Pregnancy or breastfeeding
Known HIV positive
Known allergy or hypersensitivity to any of the components of the XL184 formulation